During the past decade, Manna Research (Burlington North) conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 2 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Manna Research (Burlington North)" #1 sponsor was "Antibe Therapeutics Inc." with 1 trials, followed by "Bayer" with 1 trials sponsored, "Brigham and Women's Hospital" with 1 trials sponsored, "Pfizer" with 1 trials sponsored and "PurGenesis Technologies Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Manna Research (Burlington North)" #1 collaborator was "Boston VA Research Institute, Inc." with 1 trials as a collaborator, "Government of Canada" with 1 trials as a collaborator, "Government of Saskatchewan" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator and "Patient-Centered Outcomes Research Institute" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Manna Research (Burlington North)" are "Acute Respiratory Syndrome Coronavirus 2 (For Phase 2 Exploratory Group)" (1 trials), "Atopic Dermatitis Eczema" (1 trials), "Double Vaccinated for COVID-19 (For Phase 1 of the Study)" (1 trials), "Heart Failure" (1 trials) and "Hot Flashes" (1 trials). Many other conditions were trialed in "Manna Research (Burlington North)" in a lesser frequency.

Most popular intervention types in "Manna Research (Burlington North)" are "Biological" (3 trials), "Drug" (3 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "ATB-346 low dose" (1 trials), "ATB-346 mid-dose" (1 trials), "ATB-346 standard dose" (1 trials) and "Administration of PUR0110 (Thykamine) 0.05%" (1 trials). Other intervention names were less common.

The vast majority of trials in "Manna Research (Burlington North)" are 5 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Manna Research (Burlington North)". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Manna Research (Burlington North), undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Manna Research (Burlington North), 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".